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EDITORIAL REVIEW
Role of bone in regulation of systemic acid-base balance
The highly specialized hard structure of the bone not only
serves as the supportive framework of the body but enters into
metabolic interrelationship with it. For many years the skeleton
has been considered to be a source of buffer contributing to the
maintenance of a stable systemic pH on one hand and partici-
pating in the defense against acid-base disorders on the other
hand [1—31. The linkage between bone and the body acid-base
status can be described as both a blessing and a curse. While
bone performs this buffering process in the defense against
major systemic acid-bone perturbations, it is the very same
process of buffering which will ultimately lead to dissolution of
the bone mineral.
This paper reviews the current information on the mecha-
nisms by which bone contributes to systemic pH regulation.
The experimental and clinical evidence for the generation of
various forms of bone disease related to the buffering process
will also be reviewed.
Since bone responds to acid-base disorders through its vari-
ous constituents, it would seem appropriate to start this review
with a general description of bone composition and microenvi-
ronment.
Bone composition
Bone is a specialized connective tissue that consists of a
matrix in which various kinds of cells are dispersed.
Figure 1 provides a schematic representation of an individual
microscopic bone unit. As can be seen, the bone matrix space
is composed of both inorganic (mineral) and organic compo-
nents. It is the organizational pattern and relationship of these
two components which determines the successful mechanical
function of the skeleton. The organic, unmineralized matrix,
also called osteoid comprises about one-third of the total
skeleton weight. The osteoid consists predominantly of type 1
collagen with small amounts of proteoglycan, lipids and several
noncollagenous proteins including the recently characterized
beta-carboxyglutamic acid containing protein, osteocalcin, as
well as fibronectin, osteonectin and many others [4, 5]. The
inorganic mineral phase of bone constitutes about two-thirds of
the total matrix volume and it mainly consists of crystals of
hydroxyapatite. The term apatite implies that the arrangement
of the constitutent ions in the lattice structure of the crystals
conforms to that of naturally occurring minerals called apatites.
The general formula of the apatite minerals is Ca10(P04)6 X2.
This is not a molecular formula but specifies the relative
proportions of the smallest number of ions needed for the
smallest repeating structural unit of the crystal (Fig. 2). In bone
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mineral X = 0H and hence the term hydroxyapatite. The
hydroxyapatite crystal is extremely small and is in the order of
200 by 30 to 70 A. Such tiny crystals present an enormous
surface area estimated to be between 100 and 200 square meters
per gram of bone [6]. This large surface area renders the bone
mineral a quite impure hydroxyapatite since at the time of
crystal formation some of its constitutent ions can be replaced
by other ions of approximately the same radius, producing
minor defects in the shape of the crystals which do not affect the
overall structure [6, 7]. Thus, the calcium position can be
substituted for by lead, manganese, sodium magnesium and
strontium. Carbonate (C032) can substitute for phosphate or
for the hydroxyl ions [7]. The ionic composition of bone mineral
is summarized in Table 1 and is based on the data derived by
Armstrong and Singer [8]. The skeleton contains 99% of the
body's calcium and also 35% of the sodium, 80% of the
carbonate, 80% of the citrate and 60% of the body magnesium.
Throughout life, the bone mass is continuously turning over
by a well regulated coupling of the processes of bone formation
and resorption. During the growth years, formation exceeds
resorption and skeletal mass increases. After bone mass
reaches its peak, between ages 20 to 30 years, the rate of
formation equals the rate of resorption. After the age of 40 to 50
years, resorption exceeds formation and total skeletal mass
starts to decrease. The process of bone turnover in adults is
known as remodeling. As much as 15% of the total bone mass
normally turns over each year in the remodeling process. Bone
remodeling is carried out by the two main bone-cell types: the
osteoblast and the osteoclast (Fig. 1). The osteoblast is consid-
ered to be the cell responsible for the synthesis of the organic
matrix and its calcification. It is currently believed that the
osteoblast is important also in the process of bone resorption
which is ultimately carried out by the osteoclast through its
paracrine and endocrine properties (discussed later). Thus, the
osteoblast and not the osteoclast bears receptors for bone
resorbing hormones like PTH and l.25(OH)2D3 as well as for
cytokines such as interleukin-l [9—12]. The osteoblast also
synthesizes various bone resorbing substances such as interleu-
kin-6 and prostaglandins [13, 14]. The exact mechanism by
which the osteoblast transmits its message to the osteoclast, to
initiate bone resorption, is not entirely defined at the present.
The anatomy of the osteoblast varies from a tall cuboidal to an
almost flattened cell about 20 to 30 m in diameter. It is a
mononuclear cell, and in its most active state is rich in endo-
plasmic reticulum and ribosomes with a well developed Golgi
apparatus typical of a "protein factory" cell type. Mitochondria
are plentiful and on its exterior plasma membrane it is rich in
alkaline phosphatase. The origin of the osteoblasts is most
likely from osteoprogenitors among primitive mesenchymal
cells [15].
Osteoclasts. These cells are the major cells directly respon-
sible for bone resorption. These are large (20 to 100 im in
10 Green and Kleeman: Bone in acid-base balance
Surface osteoblasts Fig. 1. Schematic representation of the
physiological unit of bone tissue. Active
osteoblasts synthesize the bone matrix which
is composed of inorganic (mineral) and
organic (osteoid) components. Inactive
osteoblasts flatten out over the bone surfaces.
The bone area covered by these lining
osteoblasts comprises the major part of bone
tissue and is quiescent with respect to bone
remodeling. Osteoclast is a big multinucleated
cell which is primarily involved in digesting
bone tissue. (A) Vascular space. (B)
Osteocyte. This cell communicates through
protoplasmic extensions with other osteocytes
and with osteoblasts. (C) Bone canaliculi. (D)
Gap junctions between adjacent osteoblasts.
(E) Connective tissue between blood vessel
and osteoblast layer. Bone water is composed
of two compartments; the water bound to the
mineral and osteoid together with the fluid
flowing in C comprise the bone extracellular
fluid. Fluid in A and E comprise the systemic
extracellular fluid. The lining osteoblast layer
might serve as a membrane which separates
between the two compartments.
Compartmentalization of bone ECF is
strongly suggested by the existing ionic
gradients between bone ECF and systemic
ECF.
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Fig. 2. A shorthand representation of the fluorapatite unit cell. In
hydroxyapatite crystal, the fluoride (F) ion was replaced by 0H. This
abbreviated representation clearly differentiated between the triple or
"screw axis" calcium positions arranged spirally around the fluoride
ions and the columnar calcium positions designated by *• (Adapted
from Ref. 6).
diameter) cells of bone-marrow hematopoietic mononuclear cell
origin that fuse into multinucleated cells [16, 171. During bone
resorption, the cytoplasmic membrane of the osteoclast is
thrown into deep folds and clefts called a ruffled border,
increasing the cell and bone surface available for lytic activity.
As mentioned, bone resorption and form.tion are closely coor-
dinated processes. Thus, resorption cavity created by the
osteoclast is often the site of subsequent osteoblastic activity
which fills in the cavity with new bone [18]. A single turnover
cycle in a given bone unit, as characterized by coupled osteo-
elastic resorption and osteoblastic formation may last for ap-
proximately eight months [191.
As the osteoblast becomes less active in matrix formation it
flattens out, its alkaline phosphatase activity declines as does
the basophilic nature of its cytoplasm, and it becomes embed-
ded within the mineralized matrix. It is now called an osteocyte.
This cell occupies small lacunae within the bone substance and
Table 1. Ionic composition of bone mineral
Cation Anion
Ca2
Mg2
6.66
0.18
P03
C032
4.02
0.79
Na 0.32 Citrate3 0.05K 0.02 Cl 0,02
8.
Data are expressed as mmol/g of dry fat free bone. Taken from Ref.
communicates through protoplasmic extensions with neighbor-
ing cells through the bone canaliculi. (Fig. 1). Osteocytes in
their lacunae are surrounded by mature bone and in spite of not
dividing, they contribute to dissolution of mineral in their
immediate vicinity. Other inactive osteoblasts, flatten out over
the surface of bone and will be in contact with the osteocytes
via syncytial cell processes lying in bone canaliculi as diagram-
matically depicted in Figure 1. The bone surfaces covered by
these lining osteoblasts occupy about 80% of the skeleton and
they are quiescent with respect to bone remodeling, namely
they do not participate in active bone formation and bone
resorption [201. Interestingly, however, the quiescent surfaces
can be shown by autoradiography to take up radioactive cal-
cium ions [21] which in the absence of net addition of bone,
must be balanced by loss of the same number of unlabeled
calcium ion. Based on rates of calcium fluxes related to bone
remodeling (formation-resorption cycles) and the rapidity by
which the skeleton can correct for deviations in serum calcium
(hypo- or hypercalcemia), it is now clear that the instantenous
moment to moment regulation of serum calcium is handled by
movement of calcium across the large quiescent surface area
and not by the active remodeling mechanisms [20, 22].This is a
rapid process and of relatively large magnitude (50 to 100 mmol
of calcium daily). Solubilization of mineral at the pericanalicu-
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lar zone, probably by osteocytes, releases calcium which is
transferred from the interior to the exterior of the bone units
and thence into the plasma [23—25]. The bone remodeling
system on the other hand, is responsible for movement of bone
mineral between bone and body fluids during the active pro-
cesses of osteoclastic bone destruction and osteoblastic bone
formation. This process is slow, and of relatively small magni-
tude (5 to 10 mmol of calcium daily). It is apparent that while
sustained gains or losses of total bone calcium are usually
mediated only by an imbalance in the remodeling system, the
latter has very little, if any, effect on the short term homeostasis
of extracellular calcium. Were it not for the instantaneous
homeostatic mechanism, one would expect life threatening
increases or decreases in serum calcium in response to the
addition to, or removal of calcium from the extracellular fluid.
It is clearly shown in Figure 1 that aside from the large matrix
component, the bone also contains a distinct vascular space
represented by permeating blood sinusoids and small capillar-
ies. In fact, the most important factor governing density of
whole bone specimens is the amount of vascular space in
relation to the amount of bone matrix space [261. The vascular
space together with the extravascular compartment (the space
between the blood vessels and the lining osteoblasts) comprise
the systemic extracellular fluid (ECF) which bathes one side of
the osteoblast "membrane" (Fig. I). On its antisystemic ECF
side, the osteoblast is in intimate contact with the osteocytes
through their cytoplasmic extensions in the canaliculi. The fluid
that flows inside these canalilculi and in the osteocyte lacunae,
as well as fluid that is bound to the bone mineral and collagen
fibrils constitutes a subdivision of the extracellular fluid and is
called bone ECF (Fig. 1) [27].
Several lines of evidence suggest that bone ECF is compart-
mentalized [28—38]. The physiological meaning of this phenom-
enon is dual. It first means that bone fluids are not in equilib-
rium with the systemic fluid and secondly, it implies that an
anatomical or functional cellular membrane exists which by
separating bone from systemic ECF probably controls the
fluxes of ions to and from the bone substance. A strong
argument in favor of the existence of a partition between the
two compartments by a putative membrane has been provided
by the observation of a marked excess of potassium in the bone
ECF relative to the systemic ECF [29, 39]. Potassium concen-
tration in bone water may be as high as twenty-five times that of
the general extracellular fluids [40]. Although some potassium,
usually 20% or less, has to be ascribed to intracellular fluid, 80%
or more of the potassium in bone has to be assigned to the bone
extracellular fluid [31]. In fact, as an ion being confined only to
the bone water compartment, potassium is not incorporated
into the mineral phase, nor is it bound to collagen, and therefore
it is readily and completely exchangeable with the potassium of
the systemic extracellular fluid [39].
The potassium disequilibrium notwithstanding, definitive
proof for the existence of bone ECF compartmentalization
would require direct sampling of the bone fluid which at the
present is not available. However, strong data have been
provided by indirect approaches. Neuman and Ramp [221 used
a powdered cortical veal bone which was equilibrated many
times with buffers of different compositions. The buffer that did
not significantly change in composition when exposed to the
fresh bone powder was assumed to approximate the average
Table 2. Comparison of systemic extracellular fluid (plasma) with
bone ECF
Material
Electrolyte content, mM
Ca Mg K Na Pi Cl
Plasma 1.5 0.7 4 140 1.8 100
Bone "fluid" 0.48 0.4 25 125 1.8 130
Source: Ref. 22.
composition of bone fluid. The results obtained by this proce-
dure are summarized in Table 2.
If this is a valid procedure it means that [Ca] in bone ECF
is less than in serum. The Ca:P product is much less than
serum, the [K] is much higher and the [Na] and [Mg] are lower.
These data, when taken together with the formerly described
scheme for short term homeostasis of serum calcium, suggest
that whenever calcium moves from bone towards the systemic
circulation, this is done by an outwardly directed "pump"
located in the outer membrane of the lining osteoblasts. This
putative pump will be responsible for the maintenance of the
electrochemical gradient across the osteoblast cell layer.
The fact that there exists an ionic gradient between two
compartments of the extracellular fluid (systemic vs. bone)
separated by lining osteoblasts would suggest that the osteo-
blast possesses some kind of transporting epithelial cell-like
properties. Consistent with this concept is the formation of gap
junctions between processes of adjacent osteoblasts as well as
gap junctions between lining osteoblasts and the deeper osteo-
cytes [30] (Fig. 1). Such an arrangement permits cell-cell
communication as described by Loewenstein [41] and is sug-
gestive of a functional cellular syncytium. That this definite
cell-cell complex can handle a vectorial transport is also sup-
ported by the specific morphological changes of the lining
osteoblasts induced by parathyroid hormone [30]. Upon stimu-
lation of these cells with PTH an increased surface membrane
activity takes place which is characterized by the appearance of
membrane projections, microvilli and blebs. These changes are
similar to those observed in classical transporting epithelia,
such as renal collecting duct cells, in response to vasopressin, a
hormone known to stimulate solute and water movement and
therefore lend further credence to the concept of the osteoblast
being a transporting cell. In order for a cell to possess vectorial
transport properties, it needs to be polar. In fact, preliminary
data from our laboratory as well as by others have demon-
strated cell polarity with regards to active membrane calcium
pump [42] as well as the location of Na/K pump, Na/H
and Cl/HC03 exchangers (unpublished observation).
Overall, further studies are needed in order to shed more light
on the concept of a "bone membrane". Specifically, it is
unclear what the "bone membrane" is in anatomical terms. The
available data, however, permit a visualization of the physio-
logical compartmentalization between the systemic and bone
extracellular fluid. This phenomenon may govern the rate of
ionic fluxes into and out of the skeleton and probably plays a
role in the buffering mechanisms of bone in systemic acid-base
disorders.
Surface chemistry of the bone crystal
From its initial seeding induction through its growth matura-
tion and dissolution, the tiny hydroxyapatite crystal must
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Fig. 3. The volume relationship existing between the three major
components of bone matrix as that matrix becomes progressively
mineralized. Bone mineralization never became 100% or absolutely
complete but usually stopped at a point called full mineralization, that
is, about 80 to 85% of theoretically complete mineralization. At this
point, the small amount of water that was trapped or bound in the bone
matrix, no longer transported charged ions to the crystal surfaces. It
should be noted that organic bone matrix, once formed by the osteo-
blast, did not apparently shrink or expand during the mineralization
process. D = density and it reflects the water content of a given tissue.
(Adapted from Ref. 44)
interact with the water in the bone matrix. The interaction of
the crystal with its fluid environment is rather complex. For the
crystal to grow, ions must diffuse in from the circulation
(systemic ECF). Thus, bone ECF serves as a bridge between
crystal surfaces and the systemic extracellular space for the
transport of charged molecules. However, when bone mineral
is laid down in the process of mineral growth, it displaces an
equal volume of matrix water. Therefore the water spaces
between crystals or between crystals and adjacent collagen
fibers become smaller and smaller to the point where ions can
no longer diffuse at appreciable rates [43] (Fig. 3). Since crystals
cannot continue growing if ions cannot diffuse in from the
outside environment, this also means that mineralization rate
should continue maximally up to a certain critical water con-
tent. In fact, bone mineralization never becomes 100% or
absolutely complete but usually stops at about 80 to 85% of
theoretically complete mineralization [44]. It also follows that
the age of the bone is the primary determinant of its chemical
reactivity and its water content [45, 461. It is apparent that in
young bone compared to old bone, the water content is higher
and there is a constant exchange of ions between the hydroxy-
apatite crystal and its environment. The implication of the
phenomenon to our subject is obvious. Bone may actively
participate in buffering systemic acid-base disorders while it is
actively growing (that is, a young age). In contrast, in the adult
skeleton where about 80% of all free bone surfaces are quies-
cent with respect to remodeling, and less fluid is available for
ionic exchange processes to take place, there is probably a
much less active role of bone in acid-base homeostasis.
Various methods for measuring bone water have been tried,
none of which seemed to be optimal. Thus, values for water
content obtained by drying whole bones have little meaning if
care is not exercised to completely exclude marrow and other
soft tissues from the samples to be analyzed. Also, measuring
bone water compartments by using the markers usually em-
ployed to measure total water (such as urea deuterium) or
extracellular water (such as sucrose, inulin, EDTA) is ham-
pered by physiochemical interactions of these substances with
the bone crystal and matrix components [47]. With these
limitations in mind, the data by Robinson and Elliot [48, 49]
indicate that the approximate values of water in bone obtained
from young dogs ranges from 10 to 22% in cortical bone and 30
to 52% in cancellous bone. As the bone tissue increasingly
mineralizes, the percentage of total water per given volume of
bone decreases. They also defined the specific water spaces in
the bone: marrow-vascular, osteocytic and osteoid. Of the total
water content in bone, the intracellular compartment consti-
tutes about 20%. The rest, comprising the extracellular fluid, is
subdivided into systemic ECF which consists of the vascular
space and the space between blood vessels and osteoblasts and
the bone ECF which include the osteocytic lacunae, canaliculi
and matrix water (Fig. 1). In the matrix, water is bound both to
the collagen fibrils [50, 51] and to the hydroxyapatite crystals.
The latter fraction of bone ECF, also called the hydratjon
shell" constitutes the major bulk of bone ECF.
The hydration shell
For many years physicists have accepted the view that a solid
surface, when exposed to a liquid, takes on an extremely thin
film of bound solvent. The thickness of this film is not known
with certainty but hovers around an estimated mean of about
100 A. The surfaces of hydroxyapatite crystals, too, take on a
solvent layer and because the specific surface of these crystals
is so large, the total amount of solvent bound can be very high.
The physical force that creates this solvent layer depends on the
electric charge asymmetry at the crystal-solution interface. As
diagrammatically illustrated in Figure 4, in the crystal interior
each cation is completely surrounded by a restraining field of
anions, and conversely each anion is surrounded by cations. At
the surface, however, the ions are not completely shielded.
Rather, there is an interface of residual electric charge from
each surface ion projected into space (or into the solvent) as a
mosaic patchwork of positive and negative fields. This charge
asymmetry can be diluted out by forming successive layers of
polarized ions which gradually dilute the surface electric asym-
metry. The polarized ions usually consist of phosphate ions
which are naturally polarizable and of hydrated calcium ions.
Ionic calcium in the unhydrated, crystalline state is non polar-
izable but is quite polarizable by virtue of its layer of oriented
water molecules in the hydrated state (Ca 10 H2O). This
interface of hydrated calcium and polarized phosphate ions is
pictured diagrammatically in Figure 5.
It is clear that in order to fully accomplish the maintenance of
electroneutrality, the ions in the hydration shell are not fixed
and motionless but are mobile and reactive; only the electro-
static field which is responsible for the origin of the hydration
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Fig. 5. A schematic diagram of the hydration
shell which was composed mainly of polarized
hydrated calcium ions and polarized
phosphate ions. This arrangement decreased
charge asymmetry at the hydroxyapatite
crystal-water interface (adapted from Ref. 52).
shell is fixed and static. When the crystals are in solution
containing polarizable ions other than calcium and phosphate,
there will be many substitutions and replacements in the
hydration shell by ions which are normally foreign to the crystal
lattice itself (discussed later).
Since it is generated by an electrostatic field, the hydration
shell is tightly bound to the mineral crystal and will not be
removed even by high-speed centrifugal force [52]. By virtue of
its big surface area, the bone mineral will bind a large layer of
hydration shell. On a volume basis, every crystal binds a
hydration shell 1.9 times its own volume [52].
On the basis of the behavior of synthetic hydroxyapatite
crystal in aqueous suspension a four compartment system can
be delineated (Fig. 6): 1) the bulk solution; 2) the hydration
shell; 3) the crystal surface; and 4) the crystal lattice interior.
The bulk solution is the water compartment which provides the
"raw materials" for the hydration shell (that is, an in vitro
equivalent of the systemic circulation). This layer however,
differs from the hydration shell in two respects: 1) It does not
contain a high concentration of polarizable ions; and 2) it is
easily removed by centrifugation.
Aside from its electroneutralizing properties, the hydration
shell also serves as a bridge across which ionic interchange
takes place between the bone mineral and its environment. In
fact, bone can be pictured as a gigantic ion exchange column
involving the transfer of ions to and fro across the hydrated
crystal-solution interface. Some of the mineral constituent ions
can be replaced by other ions of approximately the same radius,
producing minor defects in the shape of the crystals which do
not affect the overall structure [6]. Such substitutions can occur
at the time the crystal is formed or by exchange with existing
crystals. In vitro, interactions between bone mineral and solu-
tion involve diffusion into the hydration shell, exchange at the
crystal surface and exchange within the crystals. The same
processes probably occur in vivo. When there is a net transfer
of ions from solution to the solid phase, crystal growth will
result. Mineral dissolution is associated with net ionic transfer
from solid to solution. Ion exchange, can, however, also take
place when the solid and liquid are in equilibrium (zero net
exchange). Theoretically, all ions in the extracellular fluid are
able to enter the hydration shell of bone mineral, but the depth
of further penetration is variable. The depth of penetration also
determines the magnitude of ion exchangeability between bone
and the extracellular fluid. The percentage of bone mineral
which can undergo exchange of ions with the circulation can be
determined by radioisotope measurements. Following injection
of an isotope, specific activity is determined in bone and plasma
and the ratio between the two yields the fraction of the
exchangeable ion out of the total bone content of that ion.
Based on such measurements three groups of ions can be
recognized [39] (Table 3). As can be seen, potassium and
chloride are confined to the hydration shell and are most rapidly
and completely exchangeable. Magnesium, sodium and carbon-
ate can penetrate the surface position in the crystal lattice and
are less exchangeable. Finally calcium and phosphate can
penetrate the crystal interior and are most slowly exchangeable.
The ionic interchange between the crystal and its environment
can be in one of two forms: Normal lattice ions—calcium and
Interface
Crystal interior Surface Space or solvent
- + - + - + -
- + - + - + - + - ++ - + - + - + - + - —----I
- + - + - + - + - ++ - + - + + - + -
- + - + - + - + - +
Crystal Hydration shell
eae®CDecoeeceeco
) ®1e®
j3 unpolarized phosphate ion ® unpolarized calcium ion
3D polarized phosphate ion polarized, hydrated calcium ion
Fig. 4. Schematic representation of the
electric charge asymmetry at the crystal-
solution interface (adapted from Ref. 52).
Bulk solution
(C) Crystal interior lBl Crystal surface
IA) Bound hydration shell
of polarizable ions
100 A
Fig. 6. A diagrwnatic representation of a cross section view of by-
droxyapatite crystal in aqueous suspension (adapted from Ref 52).
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Table 3. Participation of ions in hydroxyapatite-solution interaction
Penetration of ion into
IonHydration Crystal Crystal
Ion shell surface interior displaced
K — — —
Na + + —
MgSr + ++ + + CaCa + + +
Cl + — —
Citrate + — 1
CO3 + + — PO4
PU4- + + +j
F + + + 0H
phosphate can exchange for their radioactive counterparts—
isoionic exchange. Alternatively, the exchange can also be
heteroionic namely, various cations displacing calcium and
various anions displacing phosphate or hydroxyl group. The
heteroionic exchange allows a wide variety of substitutions. It
is more commonly found in the crystal surface and hydration
shell layers than in the crystal interior where space-charge
requirements are more restrictive.
In fact, this type of exchange permits the hydroxyapatite
crystal to mirror the composition of fluids in which they are
placed.
The concept of ionic interchange is crucial for full under-
standing of the mechanisms by which the skeleton participates
in buffering acute and chronic metabolic acidosis. These mech-
anisms are specifically outlined in the following sections.
Buffering of acid outside the extracellular fluid
Acute acid loads have been shown to titrate extra and
intracellular buffers [53, 54]. The state of titration of these
buffers is reflected by the level of serum bicarbonate. With
sustained acid loading, serum bicarbonate ultimately stabilizes
at some reduced level despite continuing acid retention, indi-
cating that an additional buffer system is titrated. In 1917, Van
Slyke and Cullen [55] showed that only one-sixth of an acid
load, infused into a dog, is neutralized by blood buffers,
five-sixths presumably being neutralized by bicarbonate in
interstitial fluid and lymph and by intracellular phosphate and
proteinate buffers. Swan and Pitts [53] found that when 10 mM
of hydrochloric acid per kilogram of body weight are infused
into a nephrectomized dog only 43% of the infused acid is
neutralized by bicarbonate present in extracellular fluid,
whereas 57% is neutralized by a process in which hydrogen ions
are exchanged for sodium and potassium ions which diffuse into
extracellular fluid from cells. While these initial studies focused
attention on intracellular buffers in general, it is now clear that
both soft tissue, particularly skeletal muscle, and bone play a
crucial role in buffering systemic pH changes. The weight of
experimental evidence suggests that skeletal muscle is the
critical repository of the hydrogen ions that depart from the
extracellular compartment during the very early stages of acute
metabolic acidosis [56—621. Bone is involved in buffering after
several hours following induction of acidosis [63—661 as well as
during the chronic stages of metabolic acidosis [2, 3, 67—69].
Physico-chemical reactions involved in the buffering of acid by
bone
Disturbances in the acid-base status of the organism induce
prominent changes in the chemical composition of bone. These
changes may differ between metabolic and respiratory changes,
between acidosis and alkalosis, between organic and inorganic
acidosis and most importantly, between acute and chronic
stages of acid-base perturbations. Scanning of the literature
reveals that while much emphasis has been put on the events
occurring in acute and chronic metabolic acidosis, there is
insufficient data regarding the role of bone in the buffering of
alkali load or during respiratory changes.
Data accumulated both from in vivo and in vitro studies show
that lowered extracellular pH cause buffering of protons by
bone, and a loss of bone calcium, both during acute and chronic
stages. The preparation of neonatal mouse calvariae has been
extensively used to study the in vitro response of bone mineral
to metabolic acidosis [70—73]. Using this model, Bushinsky
showed that when the culture medium is acutely acidified by
reducing the bicarbonate concentration (thus simulating a con-
dition of metabolic acidosis), there is a net influx of protons into
the neonatal mouse calvaria [70, 721. Concomitant with proton
influx there is a calcium effiux from the bone into the medium
and the two fluxes are inversely correlated [721.
During acute respiratory acidosis, produced by elevating
pCO2 in the medium, there was no net proton flux and also there
was less calcium efflux from bone during respiratory than
during metabolic acidosis. The calcium efflux in respiratory
acidosis was, in any case, significantly high compared to neutral
pH conditions [74]. The smaller calcium effiux during respira-
tory acidosis is consistent with the clinical observation that
respiratory acidosis does not appreciably increase urine cal-
cium excretion [75, 76], and suggests that under this condition
the bone plays less active role in buffering.
In metabolic acidosis, the influx of protons and efflux of
calcium are not stoichiometrically linked. Thus, in acute meta-
bolic acidosis, the buffering of protons entering the bone is not
associated with major calcium release from the skeleton [72,
73]. Measurements of proton and calcium fluxes in neonatal
mouse calvaria cultured for three hours in acidic medium,
showed that between 16 and 21 nEq of protons entered the bone
in exchange for each nEq of calcium that left [72]. Were all
buffering linked to calcium release, one would expect a stoichi-
ometric ratio of approximately 1:1 rather than 16 to 21:1. Since
most of the bone calcium is trapped within the crystal lattice,
this also means that short-term hydrogen ion buffering does not
involve major mineral dissolution.
Several lines of evidence suggest that the chemical reactions
taking place in acute metabolic acidosis involve significant
changes in the bone content of C02, as well as of sodium and
potassium. These changes are not necessarily associated with
disruption of the crystal structure of the bone mineral since in
these early phases the protons exchange with various chemical
groups which reside on the surface of the hydroxyapatite
crystal and as such are freely exchangeable (see Bone compo-
sition).
Bone CO2
Bone is the main CO2 reservoir in living organisms and
accounts for approximately 5 moles of the 6 moles total CO2
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stores in the human adult [771. For a long time it has been
assumed that carbonate (C032) was the main form of bone
C02, and that it was deeply buried within the mineral phase and
exchanging at a slow rate with the surrounding fluids [781. In
1965, Pellegrino, Blitz and Rogers [79] demonstrated that bone
carbonate is heterogenous and exists in two distinct forms, one
of which is labile in long standing acidosis and not linked to the
structure of the bone crystals. Later, Neuman and Mulryan [801
while studying the structure of synthetic apatite crystals, dem-
onstrated that 40% of the bone CO2 was rapidly exchangeable
with the CO2 of the surrounding milieu and was probably
located on the crystal surface. This labile CO2 appeared to be
bicarbonate since half of it is lost on heating according to the
formula 2HC03 — CO2 + C032 + H20. The remainder 60%
of bone CO2 is locked within the crystal lattice as carbonate
(C032) and is not at all, or poorly exchangeable. A further
support to this concept of two CO2 compartments in bone has
been provided by the works of Payart et al [81, 821 who
measured CO2 in rat cortical bone with an accurate manometric
technique and also determined the exchange of radioisotopi-
cally labelled bicarbonate between bone and the extracellular
fluid.
The first demonstration of acute changes in CO2 content of
bone in metabolic acidosis was made by Irving and Chute in
1932 [83]. They found that bone lost substantial amounts of
carbonate following four days of oral HCI administration to rats
and guinea pigs. Burnell [68] has shown that metabolic acidosis
of 5 to 10 days duration, induced by hydrochloric acid in adult
mongrel dogs, leads to a decrease in bone carbonate by approx-
imately 10% whereas metabolic alkalosis of the same duration
induces an increase in bone bicarbonate by approximately 4%.
No major changes in bone calcium and phosphorus concentra-
tions were found in either condition. He theorized that bone
CO2 loss in metabolic acidosis takes place in two stages: 1) a
rapid (hours) decrease in bone carbon dioxide without a release
of calcium and phosphorus during the first hours of metabolic
acidosis; and 2) long-term (days to weeks) mobilization of
CO32 from bone which also requires mobilization of Ca and P
[3, 84, 85]. Bettice [861 has recently shown that the total carbon
dioxide content of bone taken from rats decreases during
metabolic acidosis and is directly proportional to the extracel-
lular fluid bicarbonate concentration. The reduction in skeletal
carbon dioxide occurred within the first 24 hours after the onset
of metabolic acidosis and was found both in organic (diabetic
ketoacidosis) and inorganic (HC1 loading) types of acidosis. The
role of carbonate in the buffering of protons has also been
demonstrated in vitro by Bushinsky and Lechleider [87]. They
showed that proton-induced calcium efflux from neonatal
mouse calvariae cultured in acidic medium is due to dissolution
of bone calcium carbonate.
In respiratory acidosis, it has been suggested that bone
bicarbonate content is increased as a function of the ambient
pCO2 [81, 88]. The explanation is as follows: gaseous CO2
hydrates with bone water to form carbonic acid which dissoci-
ates into one HC03 and one H. The H is taken up by the
available carbonate ions to form a second HC03. Thus, upon
CO2 exposure, each bound CO2 molecule will lead to the
formation of two bicarbonate ions according to the following
steps.
1) CO2 + H2O- H2C03
H2C03 - H + HCO3 -
H +CO32—*HC03
This concept is consistent with the in vitro finding that in
respiratory acidosis, unlike metabolic acidosis, there is no net
proton influx into the bone [74].
Role of bone sodium potassium and magnesium in buffering
mechanisms
Aside from the large calcium pool contained in the skeleton,
bone also contains abundant amounts of other cations, mainly
sodium, potassium and magnesium [29, 39, 89]. The bone
contains 35% of total body sodium for a total amount of 1400
mmol sodium in a 70 kg body. Approximately half of this
amount is incorporated into the crystal lattice and is not readily
exchangeable with the extracellular fluid whereas the rest,
located on the crystal surface and in the hydration shell [39], is
readily mobilized. The rapidly exchangeable fraction for so-
dium in vivo is about 45% in young animals and about 25% in
the adult human [90]. Potassium which amounts to approxi-
mately 75 mmol in a 70 kg body does not enter the crystal [29],
so that apart from a small amount in bone cells, potassium
mainly resides in bone tissue fluid and in the hydration shell.
Potassium is almost completely exchangeable in vitro but only
about 60% exchangeable in vivo [91]. It is unknown what is the
exact role of the excessive potassium accumulation in the bone
extracellular fluid. Bone magnesium constitutes about 60% of
the total body stores of this cation approximating a total amount
of 800 mmols in an adult bone. Forty% of this amount is
exchangeable with the surrounding environment.
The response of bone cations to challenges of either ion
dietary deficit or metabolic acidosis seems to differ between
sodium and potassium versus magnesium. Bone magnesium
will be mobilized mainly during magnesium deficiency while
systemic pH changes do not appear to change the magnesium
stores significantly [3, 92, 93]. In contrast, bone sodium and
potassium are mobilized more easily by metabolic acidosis than
by depletion of the ion [891 and are thus considered to be a
major line of defense, particularly during acute metabolic
acidosis. A decrease in systemic pH is thought to cause the
additional protons to displace sodium and potassium from the
bone environment, resulting in an egress of sodium and potas-
sium and a buffering of systemic acidity. Evidence for sodium
hydrogen exchange is indirect and derives from both in vivo and
in vitro studies. Dogs given an acid load buffer over half of the
additional protons outside of the extracellular fluid [53]. The
proton buffering is accompanied by a release of sodium into the
extracellular fluid. In man, during the early days of metabolic
acidosis, induced by ammonium chloride, negative sodium
(—100 mEq) and potassium (—138 mEq) balances developed
prior to the loss of body calcium [3]. Induction of metabolic
acidosis by different methods in rats and dogs is followed by a
decrease in the quantity of bone sodium [60, 63, 68, 94].
Bergstrom and Wallace [89] found that average normal rat bone
contains 152 mEq of sodium and 26 mEq of potassium per
kilogram of fresh bone. When rendered acidotic by intraperito-
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neal dialysis against ammonium chloride, loss of bone sodium
and potassium took place within 48 hours. Young rats lost 21
mEq of sodium and 7 mEq of potassium per kilogram of bone.
In the adult group there was a loss of 54 mEq of sodium and 20
mEq of potassium per kilogram of bone. Also, by prelabeling
bones of adult rats and dogs with 22Na, Bettice and Gamble [57]
were able to document significant reduction in the skeletal
content of sodium within the first five hours of metabolic
acidosis. The fraction of radiolabel lost was the same whether
prelabeling was carried out over 18 hours or four weeks,
suggesting that rapidly exchanging sodium was responding to
the acid. Sodium was lost at different rates from different bones
[57, 95]. Thus decreases in sodium content were greatest in the
smaller bones of the rat, whereas in the dog the losses from flat
bones exceeded those of the long bones [57]. Using the in vitro
model of cultured neonatal mouse calvariae, Bushinsky, Levi-
Setti and Coe measured bone Na,K and Ca by employing a
high-resolution scanning ion microprobe [73]. They found that
in control medium (pH = 7.4) the calvarial bOne was rich in Na
and K relative to Ca, whereas culture in a reduced pH medium
(pH = 7.21) for three hours reduced the content of Na and K
relative to Ca by approximately 90%.
The data presented so far indicate that during the acute phase
of metabolic acidosis although there is calcium release from
bone, there is little, if any, linkage between the extent of proton
induced calcium release and the magnitude of proton buffering.
Rather, proton buffering in the acute phase, involves mostly
reduction in bone sodium, potassium and CO2 content.
Calcium fluxes in chronic acidosis were studies in the in vitro
model of cultured neonatal mouse calvariae [96]. Cells were
cultured for 99 hours in control medium or in medium acidified
(pH = 7.1) either by addition of HC1 to the medium (metabolic
acidosis) or by increasing the PCO2 (respiratory acidosis). Over
the first 48 hours there was greater net calcium efflux in
metabolic than in respiratory acidosis. Both groups showed
greater net calcium efflux than controls. However over the last
51 hours of the chronic 99 hour culture, there was net calcium
efflux from the bone only during metabolic acidosis. Thus both
in chronic and acute acidosis, decreased medium bicarbonate
(metabolic acidosis) and not just a fall in pH is necessary to
enhance net calcium efflux. This study did not provide a
stoichiometric relationship between proton and calcium fluxes.
However Lemann, Litzow and Lennon [3], carrying out bal-
ance studies in men, demonstrated an equivalence between
proton retention and calcium excretion 12 days after the dis-
continuation of oral NH4CI, suggesting that unlike acute acido-
sis, the response to chronic acidosis involves increased bone
dissolution and calcium egress into the the extracellular fluid.
Interestingly, phosphorus losses accompanied calcium losses
but these did not occur simultaneously. Thus phosphorus losses
began immediately with acid loading and stopped abruptly
when the load was discontinued. Phosphorus losses were
ultimately restored, although significant calcium losses per-
sisted even late in the recovery period. Analysis of bone
composition in patients with long standing uremia revealed a
significant decrease in calcium and carbonate which was pro-
portionate to the duration of the disease [97]. Concentrations of
phosphorus, sodium, potassium, magnesium and chloride were
not altered. This study lends further support to the notion that
skeletal sodium and potassium participate in the defense against
Table 4. Jonic fluxes in metabolic and respiratory acidosis
Metabolic acidosis
Respiratory
acidosis
Acute ChronicAcute Chronic
Hinflux ¶ I I I I ICa2efflux f f I I
Efflux of ions HCO Na C03 PO4
other than Ca
— —
f
— —
metabolic acidosis only in the acute phase, whereas in the
chronic stages calcium carbonate efflux constitute the main
buffering mechanism.
Since carbonate and not phosphorus is the major anion
accompanying calcium ion in chronic metabolic acidosis, its
source could be either the hydroxyapatite crystal itself or
alternatively, it could derive from a separate calcium carbonate
crystal phase. Regardless of the source for calcium carbonate,
it is clear that in chronic stages of metabolic acidosis, as
opposed to the acute phase, significant reduction in the total
mineral content of bone will take place along with dissolution of
the bone crystal [3, 97].
Table 4 summarizes our current knowledge regarding the
participation of various ions in the defense against systemic
acidosis, (metabolic vs. respiratory).
Role of cell versus non-cell mediated mechanisms in the process
of acid buffering by bone
Cultured medium acidified either acutely or chronically in-
duces net calcium efflux from neonatal mouse calvariae [70—74,
96]. The in vitro studies are buttressed by in vivo data in
humans and animals showing that bone salts are dissolved in
response to metabolic acidosis or following the ingestion of
ammonium chloride [3, 98—101]. Several studies have been
carried out to assess the relative role of direct dissolution of
bone mineral by protons as opposed to active osteoclastic (=
cell mediated) resorption of bone in causing the net result of
mineral loss. Dominguez and Raisz [102] studied rat fetal bones
prelabeled with 45Ca. They reported that over a wide pH range
(6.9 to 7.5) H, CO2 or HC03 concentrations did not influence
cell-mediated bone resorption. On the other hand, calcium
release from devitalized bones (termed "non-cell-mediated
calcium release") was linearly related to H concentration.
These authors concluded that their data do not support the
suggestion that acidosis (acute and chronic) stimulates osteo-
elastic resorption directly. Bushinsky et al [71, 72, 87] found
that during acute acidosis the cellular component of calcium
flux is independent of medium pH: the effect of acute lowering
of the pH is mediated through physiochemical factors alone and
does not require participation of bone cells. This conclusion
was based on the finding that both in acute metabolic and
respiratory acidosis, calcium efflux from calvariae bone was not
significantly different between live and dead (produced by 3
freeze-thaw cycles) cells. In contrast, in chronic metabolic
acidosis only live but not dead neonatal mouse calvariae
induced calcium efflux, thus establishing the role of bone cells
in mineral dissolution during chronic as opposed to acute
metabolic acidosis [96]. Goldhaber and Rabadjija [103] also
demonstrated enhanced cell-mediated calcium release from
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Table 5. Mean [Ca2l,, and pH1 during osteoclast acidification
Natbutyrate NaHCO3 NaFICO3 removal,
experimentalBasal ExperimentalBasal Experimental
flM 114 18 56 9 145 26 225 37" 110
[Ca2J1 flM —58 80 97
pH1 7.16 0.1 6.56 0.2a 7.05 0.04 7.6 005!' 7.0 0.1
pH1 —0.6 0.55 —0.48
Data are mean Sc.
a p < 0.01
b p < 0.03
Osteoclasts were isolated from the medullary bone of laying hens fed a calcium deficient diet and then cultured on glass coverslips in MEM+
10% FCS. Measurements of intracellular Ca2 and pH were done by using the fluorescent dyes, Fura-2 and BCECF, respectively. Lowering of
pH1 was achieved by two methods: I) incubating the cells with 25 mri Na-butyrate; 2) incubating the cells with 25 mM NaHCO3 followed by
removal of HCO3. In the latter condition cytosolic acidification was attributable to the operation of Cl/HC03 exchanger since it was Cl
dependent and DIDS inhibitable. (Reproduced with permission from Ref. 113).
neonatal mouse calvariae cultured for one week in acidic
medium (metabolic acidosis). They found that both mineral and
organic matrix, were removed simultaneously. Histologic ex-
amination of the extensively resorbed calvaria demonstrated
the presence of numerous osteoclasts in different stages of bone
destruction. The role of osteoclasts was also demonstrated by
the fact that thryocalcitonin, an inhibitor of osteoclastic func-
tion abolished the proton-induced calcium release. It is not
totally clear why different in vitro studies have come to different
conclusions with regard to the role of bone cells in bone
dissolution particularly under conditions of chronic metabolic
acidosis [96, 103 vs. 1021. The disagreement between the
various studies might be partially related to different cell
preparations (neonatal mouse calvariae vs. mineralized shafts
of radii and ulnae from fetal rats) or different experimental
procedure (measuring net bidirectional calcium flux vs. unidi-
rectional release of prelabeled 45Ca).
In vivo studies are consistent with enhanced cell-mediated
calcium efflux during chronic metabolic acidosis. Kraut,
Mishler and Kurokawa [1041 found that rats fed NH4CI for 16
hours developed a significant rise in serum calcium. This
abnormality was independent of any PTH effect since the rats
underwent TPTX at least 48 hours before the study. When
cell-mediated calcium release from bone was inhibited with
colchicine or calcitonin there was little change in serum calcium
in response to the acidosis, suggesting an abolition of cell-
mediated bone resorption. In another study Kraut et al [105]
found that after two weeks of oral ammonium chloride, there
was increased bone resorption in the epiphyseal but not in the
cortical or metaphyseal bone in acidemic thyroparathyroidec-
tomized rats compared with similar nonacidemic animals. Chan
et al [1061 found that in uremic rats, (5/6 nephrectomy), three
months of oral hydrochloric acid led to an increase in the
resorption surfaces with a significant diminution in trabecular
bone areas compared with uremic rats not given acid. These
bone changes were associated with high osteoclastic densities.
That study, however, did not determine the effects of acidosis
on bone in nonuremic rats. Interestingly, bone dissolution by
osteoclasts from causes other than primary systemic acidosis,
may in turn mobilize bicarbonate from the skeleton into the
systemic circulation. Such is the case, for example, in chronic
phosphate depletion which is a state associated with markedly
enhanced bone resorption [107]. Under steady state conditions,
phosphate depletion does not lead to abnormalities in acid-base
homeostasis in spite of severe bone dissolution [1081. This
phenomenon results from two coexisting and offsetting distur-
bances, both of which are related to phosphate depletion. These
are: the bone resorption and impaired renal bicarbonate reab-
sorption leading to bicarbonaturia [1091. Indeed, abolishing
bone resorption with coichicine, which blocks osteoclastic
action, resulted in metabolic acidosis, and conversely when
bicarbonaturia was eliminated by nephrectomy, metabolic al-
kalosis developed rapidly [1101. Thus, states associated with
marked bone resorption are a potential cause for metabolic
alkalosis.
Several theories have been proposed to explain the phenom-
enon of proton-mediated osteoclastic bone resorption. Lowered
pH at the resorbing bone cell-mineral interphase might contrib-
ute to rapid removal of bone mineral and speed up the exposure
of the organic matrix to various acid hydrolases elaborated by
osteoclasts or to collagenases secreted by macrophages and/or
other cells in the vicinity. This hypothesis would be in accord
with the proposal of Baron et al [1111, stating that osteoclasts
are polarized cells that secrete protons and acid hydrolases into
the bone resorbing compartment, thereby leading to the extra-
cellular digestion of the mineral and organic phases of the bone
matrix. An alternate hypothesis regards the effect of lowered
pH on the activity of various transport pathways possessed by
the osteoclasts. Acid extruding mechanisms, like the Na/H
antiporter or H translocating ATPase, may be activated by the
addition of protons to the environment. This in turn will lead to
increased secondary hydrogen ion exit, giving rise to a higher
local concentration of hydrogen ions at the cell-mineral inter-
phase and thus provide the optimum milieu for the action of
acid hydrolases secreted by the osteoclast. Recently, a C1/
HC03 exchanger has been identified in the osteoclast [112]. A
change in the activity of this exchanger, brought about by
changes in medium pH or medium bicarbonate concentration,
may affect osteoclastic function. Most interestingly, a recent
finding showed that extracellular acidification of osteoclasts
(metabolic acid) leads to a fall in both intracellular pH and
cytosolic Ca2 (Table 5). This in turn enhances formation of
podosomes which are microfilament containing structures re-
sponsible for the adhesion of the osteoclast to the bone matrix
(Fig. 7). Thus, acidification of the osteoclast environment may
directly trigger the process of bone resorption [113]. Finally, the
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Fig. 8. NaIH exchange in osteoblasts. UMR-106 cells (an osteoblast
phenotype cell line) that were depleted of Na and acidified to intra-
cellular pH (pH,) of 6.0 were loaded with the pT-I fluorescent dye,
BCECF. When added to Na-free solutions (TMA, KCI) no change in
fluorescence was observed. However, adding the cells to a media
containing 140 mri Na resulted in recovery from the acid load which
was completed when the cells attained their original resting pH, of
approximately 7.2. The acid recovery process was inhibited by amilo-
ride. Thus osteoblasts recovered from an acid pulse by a Na-depen-
dent amiloride-sensitive mechanism, indicating that they possessed
Na/H exchanger (reprinted from Ref. 117 with permission).
Fig. 7. Induction of podosomes formation by metabolic acid. These
dot-like adhesion structures were rich in F-actin and were localized in
an area within the osteoclast that binds it to bone. The expression of
podosomes was detected by a fluorescent microscope, using rhodamine
conjugated phalloidin which specifically binds F-actin. Top panel.
Osteoclasts grown in control media pH 7.4 F-actin was distributed in a
fine network with small number of podosomes observed (arrows).
Bottom panel. Osteoclasts exposed to Natbutyrate for 90 mm (pH = 7)
showed well-organized multilayered podosomes. (Reproduced with
permission from Ref. 113).
coupling between osteoclast and osteoblast activities may be
important for acid-induced osteoclastic bone resorption. Sev-
eral recent studies indicate that the osteoblast may play a
pivotal role in the bone resorption process which is ultimately
carried out by the osteoclast [1141. The osteoblast serves as a
target cell for PTH and other bone resorbing hormones and as
a potent producer of prostaglandins and various cytokines with
bone resorbing activity [9—14, 115, 116]. Based on these studies,
it is conceivable that hydrogen ion acts on osteoblasts to
produce agents that in turn stimulate osteoclasts. Also, we have
shown that the osteoblast possesses two pH regulatory mech-
anisms: Na/H exchanger (Fig. 8) and C11HC03 exchanger
(Fig. 9) [117, 118]. Thus changes in the pH of the environment
which will alter the intracellular pH might affect the activity of
either ne of these exchangers. This in turn may stimulate
osteoclastic activity by some "coupling" or paracrine mecha-
nisms.
If indeed osteoblasts play a role in proton mediated bone
resorption, it is by no means the only operative mechanism.
This idea is based on the work by Arnett and Dempster [119]
which provides a direct evidence that hydrogen ion does indeed
directly stimulate the activity of osteoclasts and does not need
to be mediated by any other cell types. They showed that
neonatal rat osteoclasts placed on thin slices of dead cortical
bone gave rise to a significant increase in the number and
surface area of "resorption pits" when the pH of the incubation
media was lowered. PTH had no additional resorptive activity
while calcitonin produced near total inhibition.
The data on cell versus non-cell mechanisms for bone resorp-
tion in respiratory acidosis are not as clear as with metabolic
acidosis. In the in vitro model of neonatal mouse calvariae
acute respiratory acidosis induces non-cell-mediated calcium
release from bone [96]. In chronic in vitro respiratory acidosis
calcium efflux was not observed at all regardless of whether the
cells are dead or alive [96]. However, studies using measure-
ments of unidirectional release of prelabeled 45Ca have shown
increased calcium release from bone through non-cell mediated
processes in chronic respiratory acidosis as well as in metabolic
acidosis [102]. There is a paucity of data from experiments
studying the effect of respiratory acidosis on bone in vivo.
Measurements of divalent ion excretion in the urine (as a
marker for bone resorption) show that neither acute nor chronic
respiratory acidosis appreciably increase urinary calcium [75,
76, 120—125]. However, in chronic respiratory acidosis there
appears to be an increase in total serum calcium [120, 126],
KCITMA
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Fig. 9. ClIHCO3IOH exchanger in osteoblasts. UMR-106 cells (an
osteoblast phenotype cell line) were loaded with the pH fluorescent
dye, BCECF and suspended in Cl-free media (Nat gluconate or
gluconate) (a,c,e). An immediate alkalinization was observed which
resulted from efflux of intracellular C1 in exchange for extracellular
base equivalents. The base equivalents included either OH ions as
demonstrated in (a), where the solution was bubbled with 100% °2 to
eliminate any C02/HCO3, or HC03 itself, as demonstrated in (c)
(solution equilibrated with air) and (e) (addition of 4 mrvi HC03 to the
solution). In each condition the alkalinization was blocked by the
stilbene derivative DIDS, which is a known blocker of Cl/HCO3
exchange (b,d,f) (reprinted with permission from Ref. 118).
suggesting either increased bone mineral dissolution or in-
creased intestinal calcium absorption (or both) coupled to
increased renal tubular calcium reabsorption.
Role of PTH
The data obtained from the in vitro experiments as well as in
vivo studies using thyroparathyroidectomized animals, indicate
that low extracellular pH (mainly metabolic acidosis) directly
induces bone dissolution regardless of the presence of absence
of PTH. One needs to realize, however, that in the intact
organism, systemic acidemia may induce either a change in the
synthesis or secretion rate of PTH or alter the activity of the
hormone as a bone resorbing agent [127—131] or do any of these
in combination. Thus PTH may play a modulatory role on the
bone resorbing effect of acidemia and conversely may augment
buffering of acid by bone.
Studies in whole animals yielded conflicting results regarding
the role of PTH. In one study, nephrectomized rats and dogs
with intact parathyroid glands were compared to thyroparathy-
roidectomized (TPTX) animals with or without replacement of
PTH. TPTX animals not given PTH showed 100% mortality
following an acute acid load and seemed to buffer a greater
proportion of the infused acid with extracellular fluid bicarbon-
ate, as they became more acidemic than PTH-replete animals
[132]. Pharmacologic doses of PTH infused into the TPTX
animals prevented the otherwise universal mortality following
HCI infusion, the animals appearing to buffer the administered
hydrogen ion load in a manner similar to that of the non-TPTX
animals. A second study [1331 showed that nephrectomized and
acutely TPTX rats buffered an acute acid load as well as
nephrectomized rats with intact parathyroid glands although
they had a higher mortality rate. However, when the acutely
TPTX animals were given exogenous PTH they buffered the
acid load to a greater extent than either TPTX non-treated rats
or non-TPTX animals. Moreover, administration of EDTA or
colchicine, agents that presumably stimulate endogenous PTH
release, led to an increase in the buffering capacity of non-
TPTX but not of TPTX animals. Also, secondary hyperpara-
thyroidism, induced experimentally by both acute and chronic
renal failure, enhanced buffering capacity of an acid load which
was dependent on the presence of intact parathyroid glands.
These observations suggest that high levels of PTH, whether
exogenous or endogenous, may enhance the extrarenal buff-
ering of an acute acid load. When TPTX animals were given
acetazolamide prior to the administration of exogenous PTH,
the hormone failed to enhance the buffering of the acid load,
thus indicating that its effect is mediated through carbonic
anhydrase. In contrast to these two studies, a third in vivo
study [134] showed that nephrectomized TPTX rats buffered
and survived an acute acid load the same as nephrectomized
sham TPTX rats. In this study, stringent measures were taken
to ensure comparable treatment and hemodynamic stability in
all the animal groups studied. Maximum attention was paid to
minimize surgical stress and to prevent hypocalcemia and
hypothyroidism prior to the experiments. Also, the non-TPTX
animals underwent an appropriate sham procedure in order to
equalize the surgical stresses between the groups. These
changes in the experimental design could partially account for
the disparity between the third study [134] and the other two
[132, 133].
In vitro experiments are also conflicting in their results.
Using the model of neonatal mouse calvariae, Bushinsky [70]
demonstrated lack of an effect of PTH (l08 M) on proton fluxes
during acute and chronic changes in media pH. In fact, PTH
was found even to inhibit proton influx in acidic medium.
Martinet al [128] examined the effects of acute acidosis in vitro
on the uptake and action of PTH in an isolated perfused canine
tibia preparation. Lowering perfusate pH to 7.0 to 7.1 (by HC1),
as compared to control pH (7.4) resulted in increased arterio-
venous difference for iPTH across the perfused bone. More-
over, both baseline and PTH stimulated cAMP generation
increased significantly under the acidic conditions. These
changes in the uptake of the hormone and its biological activity
were observed only in metabolic acidosis since acidosis induced
7.3
7.1
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by increasing perfusate pCO2 (simulated respiratory acidosis)
did not result in similar changes.
The relevance of the foregoing animal studies to the clinical
state of acidosis in man is not clear. Acute metabolic acidosis
has been found to reduce [127, 135] not to affect [1361 or only
slightly elevate serum PTH [129, 1311. Furthermore, even
during chronic metabolic acidosis, in which bone is known to be
the major source of buffer responsible for the stabilization of
extracellular bicarbonate concentration, evidence that PTH is
the critical mediator of this process is lacking. In this regard,
Lemann, Litzow and Lennon [69] induced chronic ammonium
chloride acidosis in hypoparathyroid individuals maintained on
calcium and vitamin D supplementation and compared their
response to that of normal volunteers fed equivalent amounts of
acid. Their data indicated that the two groups were not different
with respect to decrement in plasma bicarbonate concentration,
positive hydrogen ion balance and degree of hypercalciuria
observed. In another study, Coe et al [1311 found that there was
no temporal relationship between severity or onset of acidemia
and elevation in the plasma level of PTH observed during
chronic ainmonium chloride acidosis in normal volunteers. In
fact, the elevated PTH appeared to be a direct consequence of
the attendant hypercalciuria and not of the acidemic state per
se. Moreover, studies where positive hydrogen ion balance was
produced in normal subjects by prolonged administration of
ammonium chloride or feeding a high protein diet were unable
to show elevations in plasma PTH, urinary cAMP or plasma
levels of vitamin D metabolites. There was, however, signifi-
cant hypercalciuria during the chronic metabolic acidosis which
indicated that bone participated in the buffering process [135,
136].
From the currently available data, it can be concluded that
PTH does not seem to play a critically important role in
buffering an acute mineral acid acidosis. Likewise, there is not
conclusive evidence that the skeletal buffering occurring during
chronic metabolic acidosis is mediated by PTH.
Bone disease related to acidosis
The first experimental evidence for acidosis induced bone
loss derives from the classical study by Jaffe, Bodansky and
Chandler in 1932 [1371. In that study, an attempt was made to
evaluate the independent effects of each of three factors: age,
dietary calcium and chronic acid ingestion on the generation of
bone decalcification. Studying dogs with ages ranging from 3 to
18 months old who were fed ammonium chloride for about three
months, they found that the effect of acid on bone was strikingly
dependent upon the calcium intake. Thus dogs receiving an
adequate calcium diet and ammonium chloride showed less
decalcification than those receiving the acid load while on low
calcium diet. In the younger groups, ammonium chloride and
low calcium diet were synergistic with respect to the causation
of bone thinning whereas in the older animals the acid load did
not have a marked additional effect to that of low Ca diet alone.
On pathologic examination there was generalized thinning of
both cortical and trabecular bone—osteoporosis. In the young-
est age group on low calcium diet, together with ammonium
chloride there was also considerable subperiosteal and suben-
dosteal resorption, osteoclast increase and marrow fibrosis—
osteitis fibrosa. Histologic evidence of rickets or osteomalacia
was not observed in any group. The experimental evidence for
the direct bone decalcifyinig effect of chronic acidosis was
subsequently confirmed by other investigators [67, 138—141],
though not all workers found acid induced losses in cortical
bone [105, 106, 139, 140]. Some studies suggest that cortical and
trabecular bone respond differently to the same stimuli [106,
142, 143]. Thus rats with mild to moderate uremia lose cortical
bone, but in spite of an increase in osteoclast densities and
resorption surfaces, trabecular bone areas remain normal. On
the other hand, chronic mineral acidosis induced in uremic
animals leads to further increases in osteoclasts and resorption
surfaces with a significant diminution in trabecular bone areas
but no further cortical bone loss. If, indeed, uremia diminishes
cortical bone and acidosis diminishes trabecular bone, it may
reflect different mechanisms for the bone loss induced by
uremia, per se, as opposed to the acidosis associated with it.
Thus, resorption of cortical bone in uremia could be related to
secondary hyperparathyroidism which constitutes part of the
uremic syndrome.
There are two main clinical entities of chronic metabolic
acidosis in man. These are renal tubular acidosis and chronic
uremic acidosis. Aibright et al [144] made the distinction
between acidosis related to "tubular insufficiency and impaired
urinary acidification" where osteomalacia develops and "gb-
merular insufficiency", which signifies advanced renal failure.
They defined the bone changes in the latter condition as "renal
rickets" or "renal osteitis fibrosa". Osteomalacia resulting
from tubular insufficiency without glomerular insufficiency re-
sponded remarkably to combined treatment with vitamin D and
an alkalinizing salt. Once cured, only the alkalinizing salt was
necessary to prevent further bone disease. Subsequently, renal
tubular acidosis (RTA) has been shown to be a major cause of
impaired growth and short stature, particularly evident in
children [145—148]. Brenner et al [149] studied 56 children and
36 adults with RTA. He found that 67% of the patients with
proximal RTA (type II) developed radiographic skeletal abnor-
malities which consisted of rickets (widened and irregular
epiphysealmetaphyseal junction or evidence of bowing defor-
mities) in all of the children and osteopenia in many of the
adults. Children with RTA can achieve an immediate increase
in their height velocity and even reverse stunted growth when
treated with alkali in large amounts and as early in life as
possible [148, 150—158]. Likewise, the bone disease of both
children and adults with RTA can be healed by treatment with
alkali alone and healing process can begin almost immediately
after initiation of treatment [145, 154, 159—161].
It is not clear whether the pathophysiobogy of the bone
disease associated with RTA, tightly resembles the bone dam-
age observed in experimental chronic acidosis. Osteomalacia is
usually not seen in experimental acidosis [105, 106, 137] while it
is very commonly seen in children and adults with RTA [148,
149]. This disparity may be partially related to the fact that the
skeletal abnormalities in RTA are multifactorial, and could be
ascribed in addition to the acidosis per se, also to negative Ca2
balance due to hypercalciuria, secondary hyperparathyroidism,
hypophosphatemia and alteration in Vitamin D metabolism.
Hypophosphatemia is often present in non-uremic patients with
chronic metabolic acidosis and osteomalacia secondary to RTA
[145—147] and the resolution of skeletal lesions of osteomalacia
during alkali therapy is associated with marked improvement in
phosphorus balance [145, 1461. Thus alterations in the metabo-
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lism of phosphorus during chronic non uremic acidosis may be
an important determinant in the development of osteomalacia in
humans with RTA induced metabolic acidosis.
Altered vitamin D metabolism during acidosis
The literature relating to the effects of acidosis on the in vitro
synthesis, the vivo production and plasma levels of
l,25(OH)2D3 is confusing, largely because of the different
experimental approaches employed. There is a great deal of
evidence indicating that metabolic acidosis suppresses the
production of l,25(OH)2D3 in vitamin D-deficient chicks [162—
164] and rats [165—168] both in vitro [162, 166—168] and in vivo
[163—165, 169]. However, some of these experimental systems
resulted in alterations of a variety of factors known to affect
la-hydroxylase activity. Thus, the acidotic chicks used by
Sauveur et al [163] were hyperphosphatemic and the experi-
mental conditions used by Baran et al [164] resulted in a rise in
serum calcium. Obviously, both conditions could have indepen-
dent effects on the production of l,25(OH)2D3. Moreover,
Cunningham, Bickle and Avioli [1681 reported that in vitamin
D-deficient rats, the suppressive effect of acidosis on la-
hydroxylase activity was much attenuated by day 6 and was no
longer significant by day 21. Of considerable importance is the
fact that most studies showing reduced 1 ,25(OH)2D3 synthesis
in acidosis used vitamin D deficient animals. In vitamin D-re-
plete chronically acidotic animals or humans, vitamin D syn-
thesis does not seem to be altered [170]. Gafter et a! [1701 found
elevated plasma 1 ,25(OH)2D3 concentrations in acidotic vita-
min D replete rats and showed that the increments in plasma
level of 1 ,25(OH)2D3 in response to a low calcium and phos-
phate diet were normal in these animals. Similarly, Chan et al
[106] found only a nonsignificant fall in serum I ,25(OH)2D3
concentrations in acidotic uremic rats compared to non-acidotic
uremic animals. Blood levels of vitamin D metabolites in human
subjects were not altered by experimentally induced acidosis in
the studies of Adams, Gray and Lemann [1351 or Kraut et al
[171], or in patients with congenital renal acidification defects
reported by Chesney et al [172].
From the foregoing data, it seems unlikely that the occur-
rence of osteomalacia in humans with metabolic acidosis is due
to alterations in the production or metabolism of 1,25 dihydroxy-
vitamin D. The different bone pathology in human RTA com-
pared to experimental chronic acidosis should therefore be
ascribed to other factors, as stated. These factors play a role
together with the acidosis to bring about osteomalaic changes in
RTA as opposed to the osteopenia of isolated experimental
acidosis.
Uremic bone disease
The association of albuminuria and late rickets was noted as
early as 1883 by Lucas [173] but it was not until 1911 that
Fletcher [174] clearly recognized the etiologic relationship
between chronic renal disease and bone deformities. Barber
[175] reported 10 additional cases under the term renal dwarf-
ism. Parsons [176] and Teall [177] gave the first description of
the roentgenologic picture of renal rickets. The reports by
Langmead and On [178], Smyth and Goldman [179], Shelling
and Remsen [180], Albright et al [153] and others [181—183]
served to emphasize the frequent occurence of diffuse para-
thyroid hyperplasia in renal osteodystrophy. The commonest
histological abnormalities in uremic bone disease consist of
osteomalacia, osteitis fibrosa, or aplastic changes in varying
proportions. The etiology of uremic osteodystrophy is consid-
ered to be multifactorial, being related mainly to alterations in
vitamin D metabolism, phosphate retention secondary hyper-
parathyroidism and aluminum deposition in bone [184]. It is
therefore hard to evaluate the contribution of chronic uremic
acidosis, per Se, to the bone pathology. Balance studies [101] as
well as direct analysis of bone composition from patients with
chronic renal failure [97] clearly established the fact that in
renal disease bone participates in the buffering of hydrogen ions
which accumulate during uremic acidosis. The clinical signifi-
cance of this phenomenon is not clearly defined. Ginzler and
Jaffe [185], Albright and Reifenstein [186], Snapper [187] and
Bartter [188] considered that the uremic osteitis fibrosa is
mainly due to the acidosis of chronic renal failure. Moreover, in
a group of 41 children with chronic renal disease, West and
Smith [189] found acidosis in 76% of 21 stunted patients and in
none of those growing normally. It must be realized, however,
that even if uremic acidosis plays some role in the pathogenesis
of the bone disease, the effect of administered alkali on bone
pathology and resumption of normal growth is not as gratifying
as in renal tubular acidosis [99, 190—194]. Furthermore, the
effects of alkali on total body metabolism of calcium and
phosphorus, in uremic patients, have also yielded conflicting
results. Uremic acidosis differs from other forms of chronic
experimental or clinical acidosis in that negative calcium bal-
ance, when present, is due to decreased net absorption from the
gut rather than excessive renal loss [192—194]. The failure of
calcium absorption was ascribed by some investigators to
increased phosphorus excretion into the intestine which, in
turn, forms insoluble calcium phosphate complexes thus pre-
venting calcium absorption [187, 193, 195]. This theory has
been criticized on the ground that in chronic renal failure, bone
lesions may occur without hyperphosphatemia [192] and at-
tempts to increase calcium absorption by binding phosphorus in
the gut with aluminum hydroxide have usually failed. It was
suggested, therefore, that calcium malabsorption is primary and
not secondary to increased intestinal phosphorus content. An
improved calcium balance by alkali therapy in patients with
chronic renal disease has been demonstrated by Liu and Chu
[193] and by Litzow, Lemann and Lennon [99]. However,
Stanbury and Lumb [192], and Fletcher, Jones and Morgan
[190] failed to demonstrate any effect of alkali either on mineral
malabsorption or on uremic bone disease. Both abnormalities
could however be corrected by large doses of calciferol [190,
192, 194].
It is apparent that, at the present, there is not enough data to
suggest an etiologic association between uremic acidosis and
uremic osteodystrophy. Admittedly, there are several case
reports linking human uremic osteomalacia with acidosis [196—
200]. However, in some of these studies tubular acidification
defects were present in addition to renal failure while others
failed to provide histological confirmation of improvement of
bone pathology by alkali. Thus the currently available evidence
purporting to show that acidosis is a major factor in the
pathogenesis of uremic osteodystrophy is inadequate.
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Summary and unresolved issues
In this review we presented the current information on the
role of bone in the defense against acute and chronic acid loads.
It is apparent that the same process that is involved in buffering
of acid by bone will ultimately lead to reduction in bone mass
and therefore the relationship between systemic acidemia and
bone can be described as a "trade-off" phenomenon. Thus far
the major bulk of both the in vivo and in vitro studies about
bone and pH changes have concentrated on the effects of acute
and chronic metabolic acidosis. Metabolic acidosis was induced
mainly by HC1 or NH4C1 mineral acidosis. It seems that more
studies need to be done in order to address the following issues.
1) The effect of chronic respiratory acidosis should be studied
by using balance studies and comparing acid retention to
mineral loss from bone, measuring bone composition
(Na calcium and carbonate) and doing histologic and
histomorphometric studies.
2) The effect of acute and chronic metabolic alkaloses on
bone composition and bone histology have a limited number of
data from in vitro studies available, but more chronic in vivo
studies should be done to provide more information in this
regard.
3) How does organic metabolic acidosis compare to inorganic
(mineral) acidosis with respect to its effect on bone? The
ccurrently available data deals mainly with mineral acidosis.
More acute in vitro studies should be done in which either lactic
acid or ketoacids are added to cultured media to lower its pH,
and then proton and calcium fluxes between bone cells and
media can be studied. Likewise, both experimental and clinical
studies can be conducted to evaluate the effect of chronic
organic acidosis. For the clinical part, patients with chronic
lactic acidosis (D-lactic acid or L-lactic acid) can serve as study
groups. The two main chronic metabolic acidoses in humans—
RTA and zotemic acidosis—are basically mineral acidosis types
and therefore more information about the effect of chronic
organic acidosis on human bone is necessary. Also, uremic
acidosis differs from RTA inasmuch the latter is equivalent to
HC1 acidosis while in chronic renal failure acidosis is related to
the accumulation of sulfuric and phosphoric acid. While both
are considered to be mineral acids they might theoretically have
different effects on bone, especially the latter. Under the in vivo
conditions high phosphate may have an independent "anabol-
ic" effect on bone, while at the same time it may contribute to
bone disease by lowering ionized calcium, thus leading to
secondary hyperparathyroidism. Therefore to study the effect
of the "uremic acids", in isolation, one has to carry out either
an in vitro study where media of cultured bone is acidified by
adding these acids or in vivo studies in TPTX animals loaded
either acutely or chronically with phosphoric and sulphuric
acid.
4) More information is necessary regarding the effect of age on
acid-induced bone disease. Jaffe, Bodansky and Chandler [1371
have elegantly demonstrated that in younger animals the skel-
etal pathology related to acid load is much greater than in adult
animals. Whether this has any clinical implication is still un-
known. Of particular interest is the question of whether age
related or postmenapausal osteoporisis have synergistic or
additive effect to that of acid-induced bone loss.
5) While much emphasis has been put on the role of the
osteoclast in mediating acid-induced bone resorption, there has
not been much attention drawn to the role of the osteoblast
under these circumstances. This information is of utmost im-
portance in view of the currently available data about the
coupling between osteoclast and osteoblast activities. Enough
evidence has now been accumulated which indicates that
osteoblasts play a pivotal role in the bone resorption process
which is ultimately carried out by the osteoclast. It is therefore
important to study the in vitro effect of acute and chronic pH
changes on osteoblastic function and on its response to hor-
mones and growth factors.
6) The buffering of acid by bone has been mainly linked to
dissolution of calcium carbonate either by a direct action of the
acid or by the action of the osteoclast. It has recently been
shown [1181 that osteoblasts possess a C1/HC03 exchanger
which under the physiologically existing ionic gradients, ex-
trudes base from the cytosol into the bone environment. It is
thus possible that this exchanger might aid in the buffering of
acid penetrating the bone. Since Cl/HC03 exchanger in
osteoblasts is regulated by intracellular calcium [1181 as well as
by cAMP [2011, it would be interesting to see if the osteoblast
responds differently to these second messengers during acidosis
compared to neutral pH and whether this leads to altered
function of the exchanger.
It appears that more investigations are needed in order to
evaluate the role of osteoblast- osteoclast interaction in the
pathogenesis of acid-induced bone disease.
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